Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangsu Nhwa Pharmaceutical Co (002262) Fair Value & Analysis

Healthcare · CN · Market cap 19.4B CNY

Price¥18.67
Fair Value¥19.54
Upside+4.7%
Quality95/100
Evidence: High Range ¥11.49 – ¥25.62

Fair value as of: Jun 25, 2026

Analysis

Jiangsu Nhwa Pharmaceutical Co (002262) currently trades at ¥18.67, while our model-based Fair Value estimate is ¥19.54 — implying the stock looks roughly 4.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Jiangsu Nhwa Pharmaceutical Co (002262) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥19.54 versus a price of ¥18.67 — about +5% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 002262?
Our 21-model fair value for Jiangsu Nhwa Pharmaceutical Co is ¥19.54 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥18.67.
What is the quality score of 002262?
Jiangsu Nhwa Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.